Cargando…

Factors associated with treatment modification during the first year of contemporary HAART

Detalles Bibliográficos
Autores principales:	Martin, N, Perez-Valero, I, San Jose Valiente, B, Mora, M, Bernardino-Serna, JI, Gonzalez, J, Gaya, F, Zamora, FX, Pena, JM, Arribas, JR
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112927/ http://dx.doi.org/10.1186/1758-2652-13-S4-P15

Ejemplares similares

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy?
por: Vasudevan, Janani, et al.
Publicado: (2012)

High level of adherence to HAART among refugees and internally displaced persons on HAART in western equatorial region of Southern Sudan
por: Salami, O, et al.
Publicado: (2010)

Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment
por: Perez-Molina, JA, et al.
Publicado: (2010)

Trends in human papillomavirus (HPV) infection among HIV-positive women in the pre-HAART and HAART era in a Nigerian clinic
por: Onigbogi, MO, et al.
Publicado: (2010)

The prognosis of patients with dissociated virological and immunological responses to HAART
por: Jevtovic, DJ, et al.
Publicado: (2010)

HIV-1 infection in dendritic cells in HAART suppressed patients
por: Maldonado, lrvin M, et al.
Publicado: (2006)

Mesenteric fat thickness in a group of HIV patients on HAART
por: Lee, SS, et al.
Publicado: (2010)

Characteristic of HIV/AIDS infected patients at the detection and HAART initiation
por: Holban, Tiberiu, et al.
Publicado: (2014)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
por: Cassetti, I, et al.
Publicado: (2010)

High preterm delivery rates associated with initiation of HAART during pregnancy
por: Taylor, GP, et al.
Publicado: (2010)

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Anal and cervical cytologic abnormalities among HIV-infected women in the era of HAART
por: Kojic, EM, et al.
Publicado: (2009)

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

Five-year outcomes of HAART at a non-governmental treatment center in Lima, Peru
por: Castillo, N, et al.
Publicado: (2010)

Effective HAART reduces the incidence of high grade cervical neoplasia in HIV positive women
por: Morris-Harris, Deborah, et al.
Publicado: (2012)

Smoking, female gender and PI use are associated with decreasing renal function in TDF-containing HAART
por: Uglietti, A, et al.
Publicado: (2010)

Prevalence and risk factors for chronic obstructive lung disease in HIV-infected patients in the HAART era
por: Madeddu, G, et al.
Publicado: (2010)

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Efficacy and safety of therapy of chronic hepatitis B with telbivudine (LdT) in patients with HIV-infection without HAART
por: Tsarenko, SP, et al.
Publicado: (2010)

Interventions to promote adherence to Antiretroviral Therapy (HAART) among adult patients at an HIV/AIDS program in Uganda
por: Muhumuza, Simon, et al.
Publicado: (2010)

Impact of timing HAART initiation on immune status and clinical course in the cohort of the German competence network for HIV/AIDS
por: Plettenberg, A, et al.
Publicado: (2010)

Relationship between dynamics of Epstein-Barr virus and immune activation in HIV-1 infected subjects in the HAART era
por: Cattelan, AM, et al.
Publicado: (2010)

Impact of short term HAART initiated during the acute or chronic stage on SIV infection of the male genital tract
por: Moreau, Marina, et al.
Publicado: (2010)

Home visiting to an HIV positive patient prior to initiation of HAART has Lasting impact on their adherence. TASO Experience
por: Odeke, Emmanuel, et al.
Publicado: (2010)

Genetic variability and drug resistance mutations in HIV-1 infected individuals on HAART or drug naïve in Limbe, Cameroon
por: Agyingi, L, et al.
Publicado: (2012)

Does feedback of medication execution using MEMS caps aid adherence to HAART?: the MEMRI study (MEMS as Realistic Intervention)
por: Davies, S, et al.
Publicado: (2010)

Factors associated with non-adherence to HAART in HIV-positive pregnant women during pregnancy, peri- and postpartum in Lima, Peru
por: Tejada, Romina, et al.
Publicado: (2010)

Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells
por: Kløverpris, H, et al.
Publicado: (2012)

P16-49. Broad types of cytokines secreted by Gag-specific T cells from HIV infected patients on HAART
por: Montes, M, et al.
Publicado: (2009)

Prevalence of HPV in the oral cavity of HIV seropositive Indian women undergoing HAART
por: Mukherjee, Jaya, et al.
Publicado: (2014)

HAART restores the frequency of regulatory T cells (Tregs) among HIV/AIDS patients
por: Suthandhira, M, et al.
Publicado: (2014)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Immunodominant Anti-Gag SLYNTVATL Responses in HIV-patients With More Than Five Years of HAART-induced Undetectable Plasma Viremia
por: Remenar, Anica, et al.
Publicado: (2005)

Prosthetic heart valve trombosis: thrombolytic therapy as first approach
por: Gracia, J Santos, et al.
Publicado: (2004)

Neurodegeneration in the HAART era
por: Brew, Bruce J
Publicado: (2010)

A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load
por: Calcagno, A, et al.
Publicado: (2010)

Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
por: Sanchez, Carlos Alberto, et al.
Publicado: (2010)

Increase in frequencies of circulating Th-17 cells in HIV-1 infected patients with poor CD4+ T-cell reconstitution on effective HAART
por: Asthana, D, et al.
Publicado: (2014)

A magnifying glass onto renal function and serum lipid evolutions after tenofovir (TDF) and emtricitabine (FTC) in combination with atazanavir/ritonavir (ATV/r) versus efavirenz (EFV) as first-line HAART (the INCA trial)
por: Izzo, I, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_0fg1cgo7pqtsjnoet7rptim5uc